NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

NeuroPace is targeting the treatment of idiopathic generalized epilepsy (IGE), with plans to submit an FDA application in the second half of 2025. This expansion could open up a new market ...

Responsive neurostimulation has also shown promising results, particularly in patients with idiopathic generalized epilepsy (IGE). A case series reported significant reductions in seizure ...

The eruption of digital technologies and ICT has meant that, in recent decades, there has been an enormous presence of screens in people's lives and, above ...

in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy. According to IQVIA (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales ...

and primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy." The said drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

The study is scheduled to commence early this year and will be followed by a subsequent proof of concept efficacy study in dogs with epilepsy. The potential new idiopathic epilepsy therapy has ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

20%+ revenue CAGR Indication expansion to include Idiopathic Generalized and Pediatric drug-resistant epilepsy patients Become the neuromodulation category leader in efficiency and ease of use ...